User profiles for Amit Bar-Or
Amit Bar-OrProfessor, University of Pennsylvania Verified email at pennmedicine.upenn.edu Cited by 49976 |
B cells in multiple sclerosis—from targeted depletion to immune reconstitution therapies
…, M Mattoscio, R Magliozzi, A Bar-Or… - Nature Reviews …, 2021 - nature.com
Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of the …
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of the …
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
The onset of multiple sclerosis (MS) in childhood poses diagnostic and therapeutic challenges,
particularly if the symptoms of the first demyelinating event resemble acute disseminated …
particularly if the symptoms of the first demyelinating event resemble acute disseminated …
Teriflunomide and its mechanism of action in multiple sclerosis
A Bar-Or, A Pachner, F Menguy-Vacheron, J Kaplan… - Drugs, 2014 - Springer
Abstract Treatment of multiple sclerosis (MS) is challenging: disease-modifying treatments (DMTs)
must both limit unwanted immune responses associated with disease initiation and …
must both limit unwanted immune responses associated with disease initiation and …
Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
B cells are not limited to producing protective antibodies; they also perform additional
functions relevant to both health and disease. However, the relative contribution of functionally …
functions relevant to both health and disease. However, the relative contribution of functionally …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Rituximab in relapsing‐remitting multiple sclerosis: a 72‐week, open‐label, phase I trial
We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with
rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of …
rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of …
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis
A Bar‐Or, RK Nuttall, M Duddy, A Alter, HJ Kim… - Brain, 2003 - academic.oup.com
Matrix metalloproteinases (MMPs) are implicated in multiple sclerosis where one of their roles
may be to facilitate the transmigration of circulating leukocytes into the CNS. Studies have …
may be to facilitate the transmigration of circulating leukocytes into the CNS. Studies have …
Roles of microglia in brain development, tissue maintenance and repair
The emerging roles of microglia are currently being investigated in the healthy and
diseased brain with a growing interest in their diverse functions. In recent years, it has been …
diseased brain with a growing interest in their diverse functions. In recent years, it has been …
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study
A Bar-Or, JC Calkwood, C Chognot, J Evershed… - Neurology, 2020 - AAN Enterprises
… Bar-Or has served on scientific advisory boards for Biogen, F. Hoffmann-La Roche Ltd and
Genentech, Inc, GlaxoSmithKline plc, Guthy-Jackson/GGF, MedImmune, Merck/EMD Serono, …
Genentech, Inc, GlaxoSmithKline plc, Guthy-Jackson/GGF, MedImmune, Merck/EMD Serono, …
[HTML][HTML] B-cell depletion with rituximab in relapsing–remitting multiple sclerosis
Background There is increasing evidence that B lymphocytes are involved in the pathogenesis
of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal …
of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal …